Ozempic and Gastroparesis: Recognizing Symptoms vs. Confirming Diagnosis

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Awareness to Specific Risk Considerations

If you are taking Ozempic and experiencing persistent nausea, bloating, or vomiting, you may wonder whether these symptoms signal gastroparesis or something else. Decades of pharmacovigilance have established that delayed gastric emptying can arise from various causes, and distinguishing symptoms from a confirmed diagnosis is critical for proper management. This page explains the key differences and what questions clinicians should ask.

Understanding Gastroparesis and Its Link to Ozempic

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can significantly impair quality of life and may require dietary modifications, medications, or, in severe cases, surgical interventions. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus. Its pharmacology includes slowing gastric emptying, which contributes to its glucose-lowering effects but also underlies many gastrointestinal adverse reactions. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific adverse reactions reported in ≥5% of Ozempic-treated patients include nausea (15.8% for 0.5 mg, 20.3% for 1 mg), vomiting (5.0% for 0.5 mg, 9.2% for 1 mg), diarrhea (8.5% for 0.5 mg, 8.8% for 1 mg), abdominal pain (7.3% for 0.5 mg, 5.7% for 1 mg), and constipation (5.0% for 0.5 mg, 3.1% for 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data highlight a dose-dependent increase in gastrointestinal symptoms, which may be linked to the development of gastroparesis in susceptible individuals.

Mechanistic Pathways and Label Warnings

Mechanistic pathways linking Ozempic to gastroparesis involve the drug's action on GLP-1 receptors in the gastrointestinal tract, which delays gastric emptying. While this effect is intended to improve glycemic control, prolonged or excessive slowing can lead to symptomatic gastroparesis. The label does not explicitly list gastroparesis as an adverse reaction, but the high rates of nausea, vomiting, and abdominal pain—symptoms consistent with gastroparesis—suggest a potential association. The adequacy of warnings regarding this risk is a key consideration for affected patients. The current label warns of serious hypersensitivity reactions, including anaphylaxis and angioedema, but does not specifically address gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This gap may be relevant for patients who developed gastroparesis after using Ozempic and are considering legal action.

Statute of Limitations for Ozempic Claims in New York

For settlement-related considerations, affected patients in New York must be aware of the statute of limitations, which generally requires filing a lawsuit within a certain period from the date of injury or discovery of harm. In New York, the statute of limitations for personal injury claims is typically three years from the date of injury, but this can vary based on the specifics of the case, such as when the injury was discovered or when the link to Ozempic was recognized. The timeline between exposure to Ozempic and documented harm is critical. Patients who experienced gastrointestinal symptoms during dose escalation or after prolonged use should document the onset of symptoms, any medical diagnoses of gastroparesis, and the dates of Ozempic use. This documentation can help establish the causal link and ensure compliance with the statute of limitations. In summary, the evidence indicates that Ozempic is associated with significant gastrointestinal adverse reactions, including symptoms consistent with gastroparesis. The drug's label does not explicitly warn of gastroparesis, which may affect the adequacy of warnings. Patients in New York considering a settlement should consult with a legal professional to understand the applicable statute of limitations and gather evidence of the timeline between exposure and harm.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in New York?

In New York, the statute of limitations for personal injury claims is generally three years from the date of injury or discovery of harm. For Ozempic-related gastroparesis, the clock may start when the patient discovered or should have discovered the link between the drug and their condition. It is crucial to consult with a legal professional to determine the exact deadline for your case.

Does Ozempic's label warn about gastroparesis?

No, the current label for Ozempic does not explicitly list gastroparesis as an adverse reaction. It warns of serious hypersensitivity reactions but does not specifically address gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This lack of warning may be relevant for legal claims regarding inadequate warnings.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.